EMVision Medical Devices, an innovative Australian med-tech company based in Sydney and Brisbane, has made a significant leap forward by establishing its pilot commercial production line for the emu™ point-of-care brain scanner. This critical development is supported by a final $1.25 million non-dilutive cash payment from the Federal Government’s Modern Manufacturing Initiative (MMI) Medical Products Translation stream, rounding up to a total of $5 million in non-dilutive funding. This financial backing is intended to encourage the commercial production of EMVision’s non-invasive, portable, and affordable neuroimaging devices, providing a crucial boost to the company’s efforts to revolutionize medical diagnostics.
Pathway to Enhanced Neuroimaging Technology
EMVision Medical Devices, an innovative Australian med-tech firm located in Sydney and Brisbane, has made substantial progress by launching its pilot commercial production line for the emu™ point-of-care brain scanner. This pivotal achievement is bolstered by a final $1.25 million non-dilutive cash payment from the Federal Government’s Modern Manufacturing Initiative (MMI) Medical Products Translation stream, completing a $5 million total in non-dilutive funding. This crucial financial support is designed to foster the commercial production of EMVision’s non-invasive, portable, and cost-effective neuroimaging devices, offering critical support to the company’s mission to revolutionize medical diagnostics. The emu™ brain scanner aims to facilitate prompt and accurate diagnosis of brain conditions at the point of care, thereby improving patient outcomes. With this financial and governmental boost, EMVision is poised to lead advancements in the med-tech industry, enhancing healthcare delivery and potentially saving countless lives with its innovative technology.
